初始不可切除肺癌化疗或放化疗后的挽救性手术
该回顾性研究纳入2006至2017年29例初始不可切除非小细胞肺癌患者,接受化疗或放化疗后行挽救性切除。术后30天无死亡,11例出现≥3级并发症(多为心肺);初始治疗后5年总生存61%,术后5年总生存51%、无复发生存49%。初始治疗反应良好者预后更佳。
要点
- 挽救性手术总体安全,30天无死亡,但≥3级心肺并发症见于11例。
- 术后5年总生存51%、无复发生存49%,初始治疗反应良好者预后更佳。
- 17例需联合切除(支气管成形10例、肺动脉成形9例等),需充分评估心肺储备。
核心结论
- 挽救性手术可伴随心肺并发症,但总体安全,生存结局令人鼓舞,尤其初始治疗反应良好者。
研究设计与样本
- 回顾性分析2006至2017年29例初始不可切除非小细胞肺癌患者,接受化疗或放化疗后行挽救性切除(中位年龄60岁;男25例、女4例)。
主要发现
- 初始治疗至手术时间2至60个月;肺段切除1例、肺叶切除25例、双肺叶切除2例、全肺切除1例;17例需联合切除,包括支气管成形10例、肺动脉成形9例、胸壁切除4例、大血管切除1例。
- 术后30天无死亡;11例出现≥3级术后并发症,主要为心肺并发症。
- 初始治疗后5年总生存61%;术后5年总生存51%,术后5年无复发生存49%。
- 初始治疗临床III期、病理分期0-II期或对初始治疗反应良好者无复发生存预后更佳。
临床怎么用
- 对初始不可切除、化疗或放化疗后缓解或局部复发/再生的非小细胞肺癌,可考虑挽救性切除,但需评估心肺并发症风险。
- 初始治疗反应良好、病理分期0-II期者可能从挽救性手术中获得更佳生存,患者选择应结合初始分期与治疗反应。
局限性
- 单中心回顾性研究,样本量仅29例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage surgery is used for resection of locoregionally recurrent or regrowing lesions after treatment for unresectable non-small cell lung cancer. It is also used to resect lesions that have regressed after treatment and that had not initially been indicated for resection. Relationships between salvage surgery, safety, and prognosis, however, have remained unclear. METHODS: Between 2006 and 2017, 29 patients received salvage resection (median age, 60 years; 25 men and 4 women). Safety and prognosis were analyzed. RESULTS: Tumor grade at the time of initial treatment was stage III or IV in 23 and 6 patients, respectively. Twenty-two patients received chemoradiotherapy (radiation, 40-66 Gy) and 7 received chemotherapy. Time from initial treatment to surgery ranged from 2 to 60 months. Segmentectomy, lobectomy, bilobectomy and pneumonectomy were performed in 1, 25, 2, and 1 patients, respectively. Combined resections were needed in 17 patients; this included 10 bronchoplasties, 9 pulmonary arterioplasties, 4 chest wall resections, and 1 great vessel resection. There was no 30-day postoperative mortality. Grade 3 or higher-grade postoperative complications (mostly cardiopulmonary) were observed in 11 patients. Five-year overall survival after initial treatment was 61%; after surgery it was 51%. Five-year relapse-free survival after surgery was 49%. On recurrent-free survival patients with clinical stage III at the initial treatment, pathologic stage 0-II, or a good response to initial treatment showed a favorable prognosis. CONCLUSIONS: Although cardiopulmonary complications can accompany salvage surgery, the procedure is generally safe. Survival outcome is encouraging, especially in cases with good response to initial treatment.
引用
- Sonobe M, Yutaka Y, Nakajima D, et al. Salvage Surgery After Chemotherapy or Chemoradiotherapy for Initially Unresectable Lung Carcinoma. Ann Thorac Surg. 2019. PMID: 31445048. doi:10.1016/j.athoracsur.2019.06.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。